The long arm of BRAFV600E gets to mTORC1

Pigment Cell and Melanoma Research

Volumn 22, Issue 3, 2009, Pages 244-245

  Lopez Bergami, Pablo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AMINO ACID TRANSPORTER; B RAF KINASE; B RAF KINASE INHIBITOR; CD63 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE LKB1; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; RHEB PROTEIN; S6 KINASE; SORAFENIB; TEMSIROLIMUS; TUBERIN; UNCLASSIFIED DRUG; UO 126; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

APOPTOSIS; CANCER CELL CULTURE; CARCINOGENESIS; CLINICAL TRIAL; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HAMARTOMA; HUMAN; IN VITRO STUDY; MELANOMA; MELANOMA CELL; METABOLIC STRESS; NONHUMAN; PEUTZ JEGHERS SYNDROME; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SHORT SURVEY; TUBEROUS SCLEROSIS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 65549101042     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2009.00566.x     Document Type: Short Survey

References (7)

1. Inoki, K., Ouyang, H., Li, Y. Guan, K.L. (2005). Signaling by target of rapamycin proteins in cell growth control. Microbiol. Mol. Biol. Rev. 69, 79 100. (Pubitemid 40358068)
2. Karbowniczek, M., Spittle, C.S., Morrison, T. et al. (2008). mTOR is activated in the majority of malignant melanomas. J. Invest. Dermatol. 128, 980 987.
3. Lasithiotakis, K.G., Sinnberg, T.W., Schittek, B. et al. (2008). Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128, 2013 2023.
4. Ma, L., Chen, Z., Erdjument-Bromage, H. et al. (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179 193. (Pubitemid 40546387)
5. Mahoney, C.L., Choudhury, B., Davies, H. et al. (2009). LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br. J. Cancer 100, 370 375.
6. Rowan, A., Bataille, V., MacKie, R. et al. (1999). Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J. Invest. Dermatol. 112, 509 511. (Pubitemid 29171943)
7. Werzowa, J., Cejka, D., Fuereder, T. et al. (2008). Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br. J. Dermatol. doi